Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 21391.62m in AUM and 303 holdings. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

Vanguard MSCI Index International Shares ETF

VGS

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

Betashares Nasdaq 100 ETF

NDQ

NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.

Appen Limited

APX

Appen Ltd. engages in the development of human-annotated datasets for machine learning and artificial intelligence. The company is headquartered in Chatswood, New South Wales and currently employs 1,130 full-time employees. The company went IPO on 2015-01-07. The firm is engaged in providing data services for deep learning and generative artificial intelligence (AI) systems. The firm operates through two segments: Global Services and New Markets. The Global Services represent the services that the Company provides to its five United States technology customers (Global customers) using the customer's data annotation platforms and tools. New Markets comprise Appen's data annotation platform and tools (Global Product), and the enterprise, government, and China business units. New Markets also include Quadrant geolocation and Point-of-Interest (POI) data capabilities. Its Annotation Platform is the platform that both customers and internal teams used to design, run and manage data annotation tasks. The firm serves various industries, including technology, automotive, financial services, healthcare, retail, and government agencies.

CSL Limited

CSL

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria and currently employs 30,398 full-time employees. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The firm operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others.